Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow. Proteon is currently evaluating investigational vonapanitase in a Phase 3 clinical trial in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula (RC AVF) for hemodialysis and in a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD).
Error: on feed http://ir.proteontherapeutics.com/corporate.rss?c=253625&Rule=Cat=news~subcat=ALL.
Feeds are allowed from edit-content.com.
Please contact your administrator.